RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Megace ES, Megace
Synonyms :
Class :
Progestins; 17alpha-hydroxyprogesterone derivatives
Brand Name :
Megace ES, Megace
Synonyms :
Class :
Progestins; 17alpha-hydroxyprogesterone derivatives
Dosage forms & Strengths:
Adult:
Suspension:
125 mg/ml
Tablet:
20 mg
40 mg
160 mg
Indicated for reducing the pain and symptoms due to advanced breast carcinoma
40 mg orally every 6 hours daily for 2 months
It shouldn’t be used as a substitute of radiotherapy, chemotherapy, or surgery
Indicated for reducing the pain and symptoms due to advanced endometrial carcinoma
40-320 mg orally each day in divided doses
Check on the efficacy 2 months post-treatment
A maximum dose of up to 800 mg/day can be utilized
It shouldn’t be used as a substitute for radiotherapy, chemotherapy, or surgery
Not recommended for pediatrics
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may decrease the diagnostic effect when combined with metyrapone
etonogestrel/ethinyl estradiol
may diminish the serum concentration of each other when combined
may decrease the therapeutic effect of each other when combined
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
aprepitant: they may diminish the serum concentration of hormonal contraceptives
cladribine: they may diminish the serum concentration of hormonal contraceptives
fosaprepitant: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
ixazomib: they may diminish the serum concentration of hormonal contraceptives
topiramate: they may diminish the serum concentration of hormonal contraceptives
exemestane: they may diminish the serum concentration of hormonal contraceptives
anastrozole: they may diminish the serum concentration of hormonal contraceptives
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect of antifungal agents
ulipristal: they may decrease the therapeutic effect of progestins
May lead to a reduction in the concentration serum of Hormonal Contraceptives
Might lead to a reduction in the concentration serum of Hormonal Contraceptives
Might lead to a reduction in the concentration serum of Hormonal Contraceptives
Hormonal Contraceptives increase the effect of thrombogenesis of tranexamic acid
Could potentially reduce the concentration serum of hormonal contraceptives
fezolinetant: they may diminish the serum concentration of hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
could potentially lead to a reduction in the concentration serum of Hormonal Contraceptives
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
it may diminish the excretion rate when combined with interleukins, resulting in an enhanced serum level
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
tovorafenib cannot be taken with hormonal contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
mycophenolate could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Frequency undefined:
Insomnia
Mood swings
Rash
Sweating
Deep vein thrombosis
Pulmonary embolism
Thrombophlebitis
Anemia
Adrenal insufficiency
Megestrol is contraindicated in people hypersensitive to it.
Pregnancy consideration:
Not recommended
Breastfeeding warnings:
Lactating mothers should not breastfeed during the therapy
Pregnancy category:
Patient information leaflet
Generic Name: megestrol
Pronounced: me-ges-trol
Why do we use megestrol?
Megestrol treats breast cancer, endometrial cancer, cachexia due to AIDs, and cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
